| Revenue guidance | 29.0% → 39.0% Raised by 10.0 percentage points |
|---|---|
| Management target | Revenue 39.0% FY27 |
| Revenue growth | 45.7% YoY in Q1FY27. |
|---|---|
| Margins | EBITDA margin improved to 25.3% in Q1FY27. |
| Demand visibility | Strong visibility in regulated markets; 700+ filings. |
| Management confidence | High; raised guidance for FY27. |
Growth
Q1FY27 revenue hit INR 162.4 Cr (+45.7% YoY); PAT surged 119.3% YoY to INR 25.7 Cr.
Outlook
FY27 revenue guidance raised to 39%+ growth. Aiming for INR 1,000+ Cr revenue by FY29 with 30%+ EBITDA margin.
Risks
High working capital cycle (161 days) and ongoing heavy capex for Biologics and Hormone facilities.
Last quarter's promises, checked
Delivered
- FY26 Revenue INR 503 Cr → delivered INR 503 Cr (= BEAT)
- FY26 PAT INR 67 Cr → delivered INR 67 Cr (= BEAT)
- Q1FY27 Revenue ~INR 150-160 Cr → delivered INR 162.4 Cr (= BEAT)
Partly delivered
- Cash conversion cycle 170 days → delivered 161 days (= PARTIAL)
Investor Presentation filed with BSE, NSE: KPL. Summary written with AI assistance from the document.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,682.25
- Market cap
- ₹3,821 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 47.1×Sector 47.3×
- Promoter holding
- 54.86%-0.01% QoQ
- FII holding
- 3.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.
Kwality Pharmaceuticals Earnings Call Transcript: Key Takeaways
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
- Call
- Guides 30% growth
Kwality Pharmaceuticals Q1 FY27 Results: Net Profit ₹25.6 Cr, Up 115.1% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹162.4 Cr (+45.7% YoY) and net profit of ₹25.6 Cr (+115.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹25.6 Cr · +115.1% YoY
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Limited has announced the closure of its share transfer books from August 25, 2026, to August 31, 2026, for its 43rd Annual General Meeting.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited has announced its 43rd Annual General Meeting, scheduled to be held on August 31, 2026, through video conferencing.